Home Cart 0 Sign in  

[ CAS No. 5078-07-9 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 5078-07-9
Chemical Structure| 5078-07-9
Structure of 5078-07-9 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 5078-07-9 ]

Related Doc. of [ 5078-07-9 ]

Alternatived Products of [ 5078-07-9 ]

Product Details of [ 5078-07-9 ]

CAS No. :5078-07-9 MDL No. :MFCD00464862
Formula : C8H7NO2 Boiling Point : -
Linear Structure Formula :- InChI Key :RZKJWYDRDBVDJJ-UHFFFAOYSA-N
M.W : 149.15 Pubchem ID :676504
Synonyms :

Calculated chemistry of [ 5078-07-9 ]

Physicochemical Properties

Num. heavy atoms : 11
Num. arom. heavy atoms : 9
Fraction Csp3 : 0.12
Num. rotatable bonds : 0
Num. H-bond acceptors : 3.0
Num. H-bond donors : 1.0
Molar Refractivity : 41.0
TPSA : 46.26 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : Yes
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -5.92 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.62
Log Po/w (XLOGP3) : 1.81
Log Po/w (WLOGP) : 1.84
Log Po/w (MLOGP) : 0.7
Log Po/w (SILICOS-IT) : 1.87
Consensus Log Po/w : 1.57

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -2.51
Solubility : 0.46 mg/ml ; 0.00309 mol/l
Class : Soluble
Log S (Ali) : -2.4
Solubility : 0.593 mg/ml ; 0.00397 mol/l
Class : Soluble
Log S (SILICOS-IT) : -2.71
Solubility : 0.293 mg/ml ; 0.00196 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 2.15

Safety of [ 5078-07-9 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 5078-07-9 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 5078-07-9 ]
  • Downstream synthetic route of [ 5078-07-9 ]

[ 5078-07-9 ] Synthesis Path-Upstream   1~14

  • 1
  • [ 111364-29-5 ]
  • [ 5078-07-9 ]
YieldReaction ConditionsOperation in experiment
73% With trichlorophosphate In ISOPROPYLAMIDE; acetonitrile at 5 - 20℃; To a cooled (5°C) solution of (1Z)-1-(2,4-dihydroxyphenyl)ethanone oxime (9.7 g, 57.7 mmol) in acetonitrile (65 mL) and dimethylacetamide (11 mL) was added phosphorus oxychloride (5.6 mL, 60.3 mmol) drop wise. The temperature was not allowed to exceed 10°C during the addition. After 1 hrs stirring at room temperature the yellow slurry was poured on a mixture of sodium hydrogen carbonate and ice. The resulting precipitate was filtered off and dried yielding 6.3 g (73percent) the titled compound.
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2003, vol. 13, # 24, p. 4313 - 4316
[2] Patent: WO2004/5295, 2004, A1, . Location in patent: Page 99
[3] Patent: WO2005/61499, 2005, A1, . Location in patent: Page/Page column 41
[4] Patent: WO2005/37814, 2005, A1, . Location in patent: Page/Page column 35
  • 2
  • [ 89-84-9 ]
  • [ 5078-07-9 ]
YieldReaction ConditionsOperation in experiment
76%
Stage #1: With hydroxylamine hydrochloride In pyridine at 20℃; for 20.25 h;
Stage #2: With trichlorophosphate In ISOPROPYLAMIDE; acetonitrile at 5 - 20℃;
To a stirred solution of 1-(2,4-dihydroxyphenyl)ethanone (20 g, 131 mmol) in pyridine (80 mL) hydroxylamine hydrochloride (9.1 g, 131 mmol) was added over a period of 15 min in small portions at room temperature. The reaction mixture was stirred for 20 h and then diluted with water (600 mL) and extracted with ethyl acetate (2 x 250 mL). The combined organic extracts were washed with water (2 x 250 mL) and 5 percent aqueous HCI (250 mL). The solvent was removed in vacuo. Water (200 mL) was addded to the residue and then concentrated in vacuo, then toluene (200 mL) was added and concentrated in vacuo. The residue was dissolved in a mixture of acetonitrile (150 mL) and dimethylacetamide (25 mL). The solution was cooled to 5°C, phosphorus oxychloride (20.4 g, 12.2 mL, 133 mmol) was added dropwise allowing the temperature to exceed 10°C. After the addition was complete, the reaction mixture was stirred at room temperature for 1 h and then it was slowly poured into a mixture of sodium carbonate (55 g) and ice (ca 800 g). After the ice melted, the resulting slurry was filtered and the solid collected was washed with water (2 x 150 mL). The product was dried in vacuo to afford a yellow powder (14.4 g, 97 mmol, 76percent). 1H-NMR (400 MHz, DMSO-d6): δ 9.68 (br. s, 1H), 7.38 (d, J = 8.5 Hz, 1H), 6.94 (d, J = 2.2 Hz, 1H), 6.74 (dd, J = 8.5, 2.2 Hz, 1H), 2.50 (s, 3H).
Reference: [1] Journal of Organic Chemistry, 2015, vol. 80, # 17, p. 8657 - 8667
[2] Patent: WO2004/5295, 2004, A1, . Location in patent: Page 80-81
[3] Annali di Chimica (Rome, Italy), 1958, vol. 48, p. 1329,1332, 1333
  • 3
  • [ 6134-79-8 ]
  • [ 5078-07-9 ]
YieldReaction ConditionsOperation in experiment
63% With trichlorophosphate In N,N-dimethyl acetamide; acetonitrile at 0 - 20℃; for 1 h; Compound 5 (5.2 g, 31.1 mmol) was dissolved in DMA/MeCN (6 mL/18 mL), cooled to 0° C. POCl3(5.2 g, 34.2 mmol) was added dropwise to keep the inner temperature below 10° C., then stirred at RT for 1 h. The reaction was monitored by TLC. The reaction mixture was poured into crush-ice (200 mL) containing NaOAc (7.5 g, 91.4 mmol), stirred for 5 min, then stand for 30 min. The precipitate was collected by filtration, dried, afforded compound 6 (2.9 g, 63percent).
Reference: [1] Synlett, 2008, # 9, p. 1391 - 1393
[2] Patent: JP2015/214548, 2015, A, . Location in patent: Paragraph 1374; 1376; 1377
[3] Synthetic Communications, 1995, vol. 25, # 21, p. 3315 - 3321
[4] Patent: WO2007/90068, 2007, A2, . Location in patent: Page/Page column 92
  • 4
  • [ 34781-86-7 ]
  • [ 75-36-5 ]
  • [ 5078-07-9 ]
Reference: [1] Patent: US6130217, 2000, A,
  • 5
  • [ 89-84-9 ]
  • [ 6134-79-8 ]
  • [ 5078-07-9 ]
Reference: [1] Patent: US4310693, 1982, A,
  • 6
  • [ 2735-04-8 ]
  • [ 5078-07-9 ]
Reference: [1] Synthesis, 2003, # 9, p. 1373 - 1376
  • 7
  • [ 79-24-3 ]
  • [ 108-46-3 ]
  • [ 5078-07-9 ]
Reference: [1] RSC Advances, 2015, vol. 5, # 88, p. 71620 - 71626
  • 8
  • [ 850925-13-2 ]
  • [ 5078-07-9 ]
Reference: [1] Synthesis, 1982, vol. No. 1, p. 68 - 69
[2] Synthesis, 1982, vol. No. 1, p. 68 - 69
[3] Bioorganic and Medicinal Chemistry Letters, 2005, vol. 15, # 8, p. 2051 - 2055
  • 9
  • [ 5078-06-8 ]
  • [ 5078-07-9 ]
Reference: [1] Chemische Berichte, 1902, vol. 35, p. 4199
[2] Journal of medicinal chemistry, 1966, vol. 9, # 1, p. 63 - 66
  • 10
  • [ 698-31-7 ]
  • [ 5078-07-9 ]
Reference: [1] Journal of medicinal chemistry, 1966, vol. 9, # 1, p. 63 - 66
  • 11
  • [ 3163-07-3 ]
  • [ 108-24-7 ]
  • [ 5078-07-9 ]
Reference: [1] Justus Liebigs Annalen der Chemie, 1937, vol. 527, p. 71,78
  • 12
  • [ 127-19-5 ]
  • [ 6134-79-8 ]
  • [ 5078-07-9 ]
Reference: [1] Organic Process Research and Development, 2010, vol. 14, # 1, p. 72 - 84
  • 13
  • [ 23997-80-0 ]
  • [ 5078-07-9 ]
Reference: [1] Bulletin de la Societe Chimique de France, 1969, p. 2785 - 2792
  • 14
  • [ 859815-01-3 ]
  • [ 5078-07-9 ]
Reference: [1] Chemische Berichte, 1902, vol. 35, p. 4199
Same Skeleton Products
Historical Records